No Data
U.S. stocks closed: the S&P 500 Index has risen for six consecutive days as investors anticipate Trump to adjust the tariff policy.
① Amazon was forced to terminate the plan to display the impact of tariffs on commodity pages; ② China Concept Stocks fluctuated, and the Nasdaq China Golden Dragon Index fell by 0.3%; ③ Meta released an independent AI application aiming to create a personalized Asia Vets assistant; ④ Starbucks reported a Q2 revenue of 8.8 billion dollars, below market expectations.
Wall Street Today: DJIA, Nasdaq Comp and S&P 500 Rise Slightly on Trade-Deal Optimism
Novo Nordisk Shares Are Trading Higher After the Company Announced Wegovy Partnerships With Hims and LifeMD.
Wegovy is no longer in short supply. Novo-Nordisk A/S collaborates with telemedicine platforms to expand sales channels.
① Novo-Nordisk A/S announced that the company will sell the drug through the telemedicine platforms Hims & HERS, Ro, and LifeMD to expand its access channels; ② Boosted by this news, Hims & HERS surged over 24% at the opening of the US stock market on Tuesday, and Novo-Nordisk A/S's stock price also rose by 3%.
Today's Pre-Market Movers and Top Ratings | SPOT, NVO, SOFI, and More
Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!
Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.
